News
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
First half results 2023/24: Substantial acceleration in sales growth expected as temporary headwinds subside
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
Evolva enters into an agreement to sell its operations to Lallemand, securing the best possible outcome for the company and its stakeholders
Gilbert Achermann to be nominated as a new member of the Sonova Board of Directors
Gilbert Achermann to be nominated as a new member
of the Sonova Board of Directors
Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
Evolva and Breko broaden partnership by signing agreement for the exclusive distribution of Veri-teTM Resveratrol in Germany, Austria, Thailand and Vietnam
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
Lonza Prices CHF 400 Million Dual-Tranche Straight Bonds
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-Adhoc: BB Biotech AG publishes its interim report
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
EQS-News: BB BIOTECH AG: Biotech equity markets in flux: the impact of rising bond yields and shifting healthcare policies
GeNeuro and Verily Collaborate to Advance Long-COVID Research
GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, announced a collaboration with Verily, an
Capital Markets Day 2023: New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Capital Markets Day 2023:
New Mid-Term Guidance 2024 – 2028 Supported by Ramp-Up of Growth Projects
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Kuros reports a 150% increase in direct MagnetOs sales in the first nine months of 2023 and announces changes within the Executive Management
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone
Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries
Evolva and LEHVOSS sign agreement for distribution of Veri-teTM Resveratrol in over a dozen European countries
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Evolva and Nice & Green agree on improvements to financing agreement
Evolva and Nice & Green agree on improvements to financing agreement
Dominik Arnold to become new CEO of the COLTENE Group
Dominik Arnold to become new CEO of the COLTENE Group
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Evolva receives approval for Veri-teTM Resveratrol in Thailand
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA™ (ACER-001) with Acer Therapeutics
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva shareholders approve increase of the conditional capital and upper limit of capital band at extraordinary general meeting of 24 August 2023
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Evolva with good business momentum and significant progress in profitability in 1H 2023, despite major financing challenges
Kuros Biosciences Reports Results for First Half 2023
Kuros Biosciences Reports Results for First Half 2023
H1 2023 result outperforms prior year at constant exchange rates
H1 2023 result outperforms prior year at constant exchange rates